The Daily Biotech Pulse: Precision BioSciences Inks Gene Editing Pact, Athira Pharma’s Alzheimer’s Candidate Fails, Enanta Sues Pfizer Over COVID-19 Antiviral
Here's a roundup of top developments in the biotech space over the last 24 hours:
Enanta Pharmaceuticals’s Return On Capital Employed Overview
Benzinga Pro data, Enanta Pharmaceuticals (NASDAQ:ENTA) reported Q2 sales of $18.72 million. Earnings fell to a loss of $33.59 million, resulting in a 11.55% decrease from last quarter.
Evercore ISI Group Upgrades Enanta Pharmaceuticals to In-Line, Announces $39 Price Target
Evercore ISI Group analyst Liisa Bayko upgrades Enanta Pharmaceuticals (NASDAQ:ENTA) from Underperform to In-Line and announces $39 price target.
SVB Leerink Maintains Market Perform on Enanta Pharmaceuticals, Lowers Price Target to $44
SVB Leerink analyst Roanna Ruiz maintains Enanta Pharmaceuticals (NASDAQ:ENTA) with a Market Perform and lowers the price target from $58 to $44.
Enanta Pharmaceuticals Shares Fall After RSVP Phase 2b study results Miss Primary Endpoint
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) today announced the topline results for RSVP clinical study evaluating EDP-938, in otherwise healthy adults with community-acquired Respiratory Syncytial Virus (RSV).
Enanta Pharmaceuticals Reports Topline Data From RSVP Study Of EDP-938; Study Did Not Meet Primary Endpoint Of Clinical Symptom Reduction Or Secondary Antiviral Endpoints
Study Did Not Meet Primary Endpoint of Clinical Symptom Reduction or Secondary Antiviral Endpoints
Statistically Significant Percent of Subjects Who Received EDP-938 Achieved Undetectable RSV RNA at End of
10 Biggest Price Target Changes For Tuesday
Keybanc cut PubMatic, Inc. (NASDAQ: PUBM) price target from $48 to $27. PubMatic shares fell 1.5% to $18.71 in pre-market trading.
Earnings Scheduled For May 9, 2022
Companies Reporting Before The Bell
• Atlantica Sustainable (NASDAQ:AY) is likely to report quarterly loss at $0.08 per share on revenue of $277.90 million.
Enanta Pharmaceuticals Doses First Subject In A Phase 1 Clinical Study Of EDP-235, Its Oral 3CL Protease Inhibitor Specifically Designed For The Treatment And Prevention Of COVID-19
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it has dosed the first subject
Where Enanta Pharmaceuticals Stands With Analysts
Enanta Pharmaceuticals (NASDAQ:ENTA) has observed the following analyst ratings within the last quarter: